Drugs / CD123 CAR-T cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03796390 | Dec 2018 → Nov 2020 | acute myeloid leukemia | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04272125 | Dec 2019 → Dec 2023 | acute myeloid leukemia | Chongqing Precision Biotech Co., Ltd | Unknown | No outcome recorded |
| Phase 1/2 | NCT04265963 | Sep 2019 → Dec 2023 | acute myeloid leukemia | Chongqing Precision Biotech Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD123 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04265963 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T cell immunotherapy (CAR-T)” NCT03796390 ↗ |
| Route | Intravenous | “administered intravenously” NCT04272125 ↗ |